Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Irvine, California 92612


Purpose:

Port wine stain are a congenital, progressive vascular malformation of human skin. The pulsed dye laser is approved by the Food and Drug Administration for the treatment of choice. However, the degree of port wine stain blanching seen following pulsed dye laser treatment remains variable and unpredictable. If the ultimate standard required is complete lesion blanching, the average success rate is below 10%, even after undergoing numerous pulsed dye laser treatments. Moreover, less than 50% of patients achieve 50% fading of their Port wine stain in response to pulsed dye laser therapy.


Study summary:

The researchers' specific aim is to determine whether the use of the pulsed dye laser operating at a wavelength of 577 nm will improve therapeutic outcome as compared to a pulsed dye laser operating at 595 nm. The researcher can treat port wine stain treated using a pulsed dye laser operating at a wavelength of 577 nm and the other half at a wavelength of 595 nm. The researcher can determine that the 577 nm pulsed dye laser improved port wine stain blanching responses more than the areas treated with 595 nm. The degree of port wine stain blanching which will determine by visible reflectance spectroscopy skin imaging device measurements. Post-treatment blanching responses can compare with pre-treatment measurements of port wine stain fractional blood volume.


Criteria:

Inclusion Criteria: - Port Wine Stain suitable for comparison testing - Age > 6 months of age; minor will be accompanied in the room by parents or guardians during laser treatment - Apparent good health as documented by medical history - Ability to understand and carry out subject instructions Exclusion Criteria: - History of photodermatoses or skin cancer - Any therapy within the previous two months to the proposed Port Wine Stain treatment sites - Inability to understand and carry out instructions


NCT ID:

NCT00573729


Primary Contact:

Principal Investigator
John S Nelson, M.D., Ph.D.
Beckman Laser Institute University of California Irvine


Backup Contact:

N/A


Location Contact:

Irvine, California 92612
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.